Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G2A | P14555 | 3/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.46 |
| ▸ | MAPT | P10636 | 7/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.45 |
| ▸ | HPGD | P15428 | 4/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | TP53 | P04637 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.44 |
| ▸ | RELA | Q04206 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2012625 | 0.76 | PLA2G2A (0.50) | PLA2G2ACYP1A2MAPTALDH1A1KDM4E | |
| SCHEMBL2014731 | 0.75 | PLA2G2A (0.49) | PLA2G2ACYP1A2MAPTALDH1A1KDM4E | |
| SCHEMBL17080124 | 0.74 | KDM4E (0.52) | CYP1A2ALDH1A1KDM4EHPGDSMN1; SMN2 | |
| SCHEMBL17080148 | 0.74 | KDM4E (0.56) | CYP1A2ALDH1A1KDM4EHPGDSMN1; SMN2 | |
| SCHEMBL2014297 | 0.72 | L3MBTL1 (0.58) | MAPTALDH1A1KDM4EHPGDSMN1; SMN2 | |
| SCHEMBL17080275 | 0.72 | MEN1 (0.44) | MAPTALDH1A1KDM4EHPGDSMN1; SMN2 | |
| SCHEMBL30786194 | 0.72 | MEN1 (0.44) | MAPTALDH1A1KDM4EHPGDSMN1; SMN2 | |
| SCHEMBL28326285 | 0.71 | POLB (0.58) | MAPTALDH1A1KDM4EHPGDSMN1; SMN2 | |
| SCHEMBL9869415 | 0.70 | LMNA (0.53) | CYP1A2MAPTALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL9869063 | 0.70 | LMNA (0.53) | CYP1A2MAPTALDH1A1KDM4EHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9120822-B2 | Tricyclic antibiotics | BASILEA PHARMACEUTICA AG (CH) | 2015-09-01 | — | — | US | disclosed |
| US-20150072975-A1 | TRICYCLIC ANTIBIOTICS | BASILEA PHARMACEUTICA AG | 2015-03-12 | — | — | US | disclosed |
| US-8927541-B2 | Tricyclic antibiotics | BASILEA PHARMACEUTICA AG (CH) | 2015-01-06 | — | — | US | disclosed |
| EP-2513115-B1 | TRICYCLIC ANTIBIOTICS | BASILEA PHARMACEUTICA AG (CH) | 2013-10-09 | — | — | EP | disclosed |
| EP-2513115-A1 | TRICYCLIC ANTIBIOTICS | Basilea Pharmaceutica AG (CH) | 2012-10-24 | — | — | EP | disclosed |
| US-20120245345-A1 | TRICYCLIC ANTIBIOTICS | BASILEA PHARMACEUTICA AG (CH) | 2012-09-27 | — | — | US | disclosed |
| WO-2011073378-A1 | TRICYCLIC ANTIBIOTICS | BASILEA PHARMACEUTICA AG (CH) | 2011-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120245345-A1 | TRICYCLIC ANTIBIOTICS | CBR1, CBR3, C1S | PLA2G2A 3163/4885CYP1A2 190/4885MAPT 4863/4885 |
| US-20150072975-A1 | TRICYCLIC ANTIBIOTICS | TREH, MRPL21, SPOUT1 | PLA2G2A 4774/4885CYP1A2 225/4885MAPT 3446/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.